Feasibility of Targeting Traf2-and-Nck-Interacting Kinase in Synovial Sarcoma.

ABSTRACT:

Background

The treatment of patients with metastatic synovial sarcoma is still challenging, and the development of new molecular therapeutics is desirable. Dysregulation of Wnt signaling has been implicated in synovial sarcoma. Traf2-and-Nck-interacting kinase (TNIK) is an essential transcriptional co-regulator of Wnt target genes. We examined the efficacy of a small interfering RNA (siRNA) to TNIK and a small-molecule TNIK inhibitor, NCB-0846, for synovial sarcoma.

Methods

The expression of TNIK was determined in 20 clinical samples of synovial sarcoma. The efficacy of NCB-0846 was evaluated in four synovial sarcoma cell lines and a mouse xenograft model.

Results

We found that synovial sarcoma cell lines with Wnt activation were highly dependent upon the expre

SUBMITTER: Sekita T 

PROVIDER: S-EPMC7281028 | biostudies-literature | 2020 May

REPOSITORIES: biostudies-literature